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Autism spectrum disorders (ASD) are a heterogeneous group of neurodevelopmental
disorders characterized by problems with social communication, social interaction, and
repetitive or restricted behaviors. ASD are comorbid with other disorders including
attention deficit hyperactivity disorder, epilepsy, Rett syndrome, and Fragile X syndrome.
Neither the genetic nor the environmental components have been characterized well
enough to aid diagnosis or treatment of non-syndromic ASD. However, genome-wide
association studies have amassed evidence suggesting involvement of hundreds of genes
and a variety of associated genetic pathways. Recently, investigators have turned to
epigenetics, a prime mediator of environmental effects on genomes and phenotype, to
characterize changes in ASD that constitute a molecular level on top of DNA sequence.
Though in their infancy, such studies have the potential to increase our understanding of
the etiology of ASD and may assist in the development of biomarkers for its prediction,
diagnosis, prognosis, and eventually in its prevention and intervention. This review focuses
on the first few epigenome-wide association studies of ASD and discusses future
directions.
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Introduction
Autism spectrum disorders (ASD) are defined diagnostically by impaired social communication,
restricted interests, and repetitive behaviors, defined hereafter as endophenotypes. Such endophe-
notypes are thought to result from disordered neurodevelopment, although the precise etiology is
unknown (1–3). Other common, but not universal, features of ASD include attention deficits, sen-
sory and motor abnormalities, cognitive impairment, and epilepsy (1, 3). Gastrointestinal dysbiosis
and impaired immune and mitochondrial function have been observed in subsets of individuals
with ASD, although the association of these endophenotypes with neurodevelopment is yet unclear
(see also Section “The Genetics of Autism”). ASD have a prevalence of approximately 1% and strong
male bias (male:female ratio approximately 4:1).
The reference standard tools for diagnosing ASD using a multidisciplinary team include the
Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Statistical
Classification of Diseases and Related Health Problems (4, 5). To aid diagnosis, other tools have
been developed, with the most widely used being the Autism Diagnostic Interview-Revised (ADI-
R) and the Autism Diagnostic Observation Schedule (ADOS) (reviewed in Ref. (6)). Another
tool sometimes used as an initial screen in childhood, the Childhood Autism Spectrum Test
(CAST), is a questionnaire that measures social and communication skills in a non-clinical
setting (7).
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The Genetics of Autism
Autism spectrum disorders, like all other human conditions and
diseases, are likely caused by a combination of genes, envi-
ronment, and the interaction between the two (Figure 1). The
degree of variation in ASD phenotype caused by genetic variation
has been estimated at between 40 and 90% ((8) and references
therein). Specific genetic variations in ASD have been studied
by measuring single nucleotide variants (SNVs), copy number
variants (CNVs) and cytogenetic abnormalities (reviewed in Refs.
(9–11)). To date, hundreds of genes have been linked to ASD
using such approaches. However, reproducible genetic variants
have been linked with a very small percentage of cases of non-
syndromal ASD. Although this underscores the phenotypic het-
erogeneity of ASD, we now know that common variants of small
effect and rare and de novo variants of large effect can combine
to influence risk for ASD (12). For an up-to-date database of
ASD-associated genes, the reader is referred to the Simons Foun-
dation Autism Research Initiative (SFARI) ASD gene database
(https://gene.sfari.org/ (13)). This resource reviews the evidence
for each gene’s association with ASD and assigns a score, from
6 (“not supported”) to 1 (“high confidence”). Genes associated
with syndromic ASD are categorized separately. As of April 2015,
there were 667 genes in this database, with 16 listed as “high
confidence” (Table 1). Some, such as CHD8, DYRK1A, and TBR1
are active in early development. Of particular interest, half of
these genes have a proven or suspected function in networks
that involve epigenetic change, such as transcription factors (e.g.,
ADNP, ASH1L, CHD8) and ATP-dependent chromatin remod-
ellers (e.g., ARID1B). This reflects the findings of many genome-
wide genetic studies (14–18). A second major genetic network
identified in ASD is neurodevelopment, including cell signal-
ing (15, 16, 18). As early development is accompanied by rapid
epigenetic change, many genes are likely to function in both
pathways. This is evidenced by dual functions for genes such as
CHD8 (19) and ARID1B ((20) and discussed in Ref. (21)). A third
frequently identified ASD-associated genetic network involves
synaptic function, including related networks of postsynaptic den-
sity protein complexes, neuronal cell adhesion and the balance of
excitation and inhibition (9, 10, 16–18, 22). This is likely to be due
at least in part to genes with a dual role in synaptic development
and function (reviewed by Chen et al. (23)). One other network
FIGURE 1 | Diagrammatic representation of how genetic and
epigenetic changes combine and interact in the etiology of ASD as
summarized in the text. Epigenetic load (from prenatal environment and
stochastic variation) and genetic load (from familial and de novo variation)
interact to compromise neurodevelopmental, immune, oxidative stress, and
mitochondrial pathways identified through studies of ASD genetics,
physiology, expression, and/or methylation. We have highlighted in gray the
putative involvement of specific genes mentioned in this review for which
evidence has come from candidate and genome-wide studies. Examples of
genes implicated in epigenetic load for ASD are ZFP57 and MECP2. In
addition, sequence variants of genes involved in the control of expression
such as ADNP, ASH1L, CHD8, and ARID1B (not shown), will induce
epigenetic changes within genes that they regulate. Evidence has come from
studies of epigenetics and gene expression for the dysregulation of OXTR,
GAD1, RELN, EN2, and ENO2 during neurodevelopment in ASD. Further
interactions will occur between specific genes and specific prenatal
environments. Over a certain threshold of genetic and epigenetic
dysfunction, development is decanalized and neurodevelopment disrupted.
This includes defects in synaptic function, connectivity, and morphogenesis
and would lead to abnormal brain maturation, neural circuity dysfunction,
characteristic endophenotypes of ASD. Further, postnatal environments may
also contribute to severity of symptoms.
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TABLE 1 | Genes for which there is high confidence of association with ASD from genetic evidence (https://gene.sfari.org/ (13)).
Abbreviation Name Protein function
ADNP Activity-dependent neuroprotector homeobox Vasoactive intestinal peptide, neuroprotective factor, transcription factor (E)
ANK2 Ankyrin 2, neuronal Cytoskeletal and cell membrane protein
ARID1B AT rich interactive domain 1B (SWI1-like) ATP-dependent chromatin remodeller (E)
ASH1L Ash1 (absent, small, or homeotic)-like (Drosophila) Transcriptional activator, cell-cell tight junctions (E)
ASXL3 Additional sex combs like 3 (Drosophila) Possible regulator of transcription (E)
CHD8 Chromodomain helicase DNA binding protein 8 Transcriptional repressor involved in early development (E)
DYRK1A Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A Protein kinase involved in signaling and early development
GRIN2B Glutamate receptor, inotropic, N-methyl D-aspartate 2B Glutamate receptor involved in long-term potentiation and synaptic transmission
POGZ Pogo transposable element with ZNF domain Possible transposase and transcription factor (E)
PTEN Phosphatase and tensin homolog (mutated in multiple advanced
cancers 1)
Tumor suppressor involved in signaling and mitochondrial function
SCN2A Sodium channel, voltage-gated, type II, alpha subunit Sodium channel expressed in the brain
SETD5 SET domain containing 5 Likely chromatin protein (E)
SHANK3 SH3 and multiple ankyrin repeat domains 3 Postsynaptic density synapse scaffold protein
SUV420H1 Suppressor of variegation 4-20 homolog 1 (Drosophila) Likely chromatin protein (E)
SYNGAP1 Synaptic Ras GTPase activating protein 1 Postsynaptic density synapse protein
TBR1 T-box, brain, 1 Likely transcription factor associated with early cortical development (E)
(E) indicates a proven or likely epigenetic function based on published data (reviewed in Ref. (14–18)).
highlighted by genetic studies of ASD is mitochondrial function
(16) and evidence suggests that disruption of this network may
compromise neurodevelopment, agreeing with the elevated levels
of mitochondrial disease seen in ASD (reviewed in Ref. (24)). It
is also important to note that, via protein–protein interactions
and the regulation of multiple genes by sequence-specific factors,
all of the above networks are in some way interconnected (25).
In Figure 1, we summarize these genetic pathways to ASD via
disrupted neurodevelopmental and other gene pathways.
It has been proposed that, rather than resulting from dys-
function of specific genes, ASD result from the dysfunction of
specific genetic pathways (26), an extension of an early “poly-
genic hypothesis” for the origins of neurodevelopmental dis-
orders (27). These ideas also agree with the threshold model
of disease (28, 29) in which ASD phenotypes become appar-
ent only after a certain burden of genetic risk alleles has been
reached; burden could apply within specific pathways too. These
ideas could help explain the apparent genetic heterogeneity of
ASD and may lead to potential therapies based on these path-
ways. The story may be yet more intricate; complex eukaryotes
have inbuilt genetic redundancy and homeostatic mechanisms
and can buffer or compensate for the loss of a particular gene
within a pathway (30, 31). However, such homeostatic mecha-
nisms may not always fully compensate, resulting in subtle and
possibly tissue-specific maladaptive phenotypic change, defined
as decanalization (32). This concept is based on Waddington’s
original definition of canalization as the ability of an organ-
ism to maintain phenotypic fidelity in the face of environ-
mental and/or genetic perturbation (33). It has been suggested
that the recently evolved neocortex may not have had time
to develop such robust buffering mechanisms, and that conse-
quent decanalization and associated gene-environment interac-
tions could contribute to the pathogenesis of neurodevelopment
disorders including schizophrenia and ASD (34, 35). Alterna-
tively, the neocortex is more complex and thus more prone to
disruptions than other brain areas, so that developing compen-
sations for disruptions might be harder because of this inherent
higher complexity.
Going beyond genetic associations, alterations in other cellular
processes have begun to be found in ASD. Studying changes
to physiology, gene expression, and the epigenetic states that
contribute to ASD phenotype along with genetics, has begun
to broaden our understanding of ASD and will eventually, in
combination, lead to better methods of diagnosis, prognosis and
even treatment of ASD. For the rest of this review, we focus on
these mechanisms, briefly reviewing physiology and gene expres-
sion and focusing mostly on epigenetics, and in particular, the
genome-wide studies of ASD published to date.
The Physiology of Autism
Autism spectrum disorders are currently defined on the basis
of behavioral observations only. However, evidence is growing
rapidly that is beginning to define ASD in physiological terms
(reviewed in Ref. (36–39)). If consolidated, such information may
help to phenotypically define ASD, inform on prognosis and even
help identify possible causes.
At the center of the ASD-associated physiological definition
is the process of inflammation. Evidence for the association of
inflammationwithASD comes from a relationship between famil-
iar autoimmune disorders and ASD, discovery of a physiologi-
cally defined shift to a pro-inflammatory state (exemplified by
cytokines) in the brain and blood in ASD, from animal models
of ASD and from the positive response to immune suppressive
medications (e.g., corticosteroids) in those affected by ASD (36–
39). Affected immune cells include the microglia in specific brain
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regions (supported by post mortem and neuroimaging data) and
cells of the innate and adaptive immune system in the blood.
Two other main physiological characteristics of ASD have been
reported and reviewed: elevated levels of oxidative stress and
mitochondrial dysfunction in the blood and brain (reviewed in
Ref. (9, 37, 40)). Moreover, there are emerging links between
inflammation, oxidative stress, and mitochondrial function and
although the direction of associations are as yet unclear, a number
of studies have found a relationship between the degree of disrup-
tion of these pathways and the severity of ASD (37). However, a
lot more work needs to be done to test these associations, address
the issue of causality and to use this knowledge to benefit those
with ASD.
A further pathway implicated in ASD is intestinal dysbiosis as
evidenced by a reducedmicrobiome complexity in ASD (reviewed
in Ref. (38, 40–42)). However, again, issues of cause/effect and
consistency of data need to be addressed before such data can be
put to clinical use.
Gene Expression and Autism
As the expression levels of a gene are largely influenced by the
epigenetic state of its surrounding regulatory regions, it is first
worth briefly reviewing genome-wide studies of gene expression
inASD. For amore extensive review, please refer to a paper written
by Voineagu and colleagues (43). Below, we review the major
findings from this publication and subsequent literature (44–49).
Table 2 lists the samples, tissues, and major molecular path-
ways identified by these studies. The most commonly identified
pathways have been inflammation and immunity (eight studies),
neurodevelopment (four studies), synaptic function (four stud-
ies), steroid biosynthesis and metabolism (three studies), and
circadian rhythm (two studies). Immune and inflammatory path-
ways have featured rarely in the results of genetic studies of ASD
(for an exception, see Ref. (18)) but are no surprise in studies of
expression because immune dysfunction in brain and blood have
been well documented in ASD (38, 50, 51). “Neurodevelopment”
is an expected pathway, as ASD are primarily a disorder of brain
development. Steroid pathways, particularly those linked with
androgens, may relate to the male predominance of ASD, but have
also not been identified as common pathways disrupted by genetic
change in ASD (52).
Epigenetics
Epigenetics describes the molecular factors that form complexes
at regulatory regions of DNA to influence genetic activity without
changing the primary DNA sequence. Such factors are usu-
ally inherited through mitosis but their meiotic (transgenera-
tional) inheritance is controversial due to the expansive epigenetic
remodeling that happens twice per generation – during gameto-
genesis and during very early embryonic development (64–66).
Epigenetic change is initiated by sequence-specific proteins or
RNAs. This results in the recruitment of epigenetic “writers” or
transferases that add specific small molecules such as the methyl
and acetyl groups to DNA or its packaging proteins – the histones.
In turn, each locus recruits specific combinations of “readers” –
molecules that bind modified DNA and histones. Finally, these
TABLE 2 | Summary of genome-wide studies of expression in ASD.
Reference Samples (cases/controls)a Tissue source Pathways identified
(53) 3/3b LCLs Neurodevelopment
(54) 49/12 PBLs Immune and inflammatory response (mediated by NK cells), cytotoxicity
(55) 15/15 LCLs Cell communication, immune and inflammatory response
(56) 20/– LCLs Steroid hormone metabolism
(57) 86/30 LCLs Steroid hormone metabolism, circadian rhythm
(58) 52/27 PBLs immune and inflammatory response (mediated by NK cells)
(59) 20/22 LCLs Neurodevelopment, synaptic function (long-term potentiation)
(60) 10/23 CB,PFC,CN Synaptic function
(61) 6/6 TC Immune and inflammatory response
(62) 19/17 FC,TC,CB Synaptic function, immune and inflammatory response
(46) 32/40 PFC,FC Microglial function, immune response, neuronal activity
(63) 70/60 PBLs Neurodevelopment; signaling; skeletal development
(48) 20/18 PBLs Ribosome function, spliceosome function, mitochondrial, immune and inflammatory
response, calcium signaling
(47) 170/115 PBLs Neurotrophic signaling, notch signaling; synaptic function (long-term potentiation)
(45) 60/68 PBMCs Immune and inflammatory response; hemoglobin metabolism
(49) 3/3b,c LCLs Neurodevelopment, skeletal development, gastrointestinal development, steroid hormone
metabolism, circadian rhythm
LCLs, lymphoblastoid cell lines; CB, cerebellum; PFC, prefrontal cortex; CN, cingulate nucleus; FC, frontal cortex; TC, temporal cortex.
aSome cases also had other syndromes such as Fragile X.
bThree discordant twin pairs, two with unaffected siblings.
cMicroRNAs analyzed. Adapted from Ref. (43).
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readers can be removed by “erasers” such as demethylases or
deacetylases. A further set of proteins –ATP-dependent epigenetic
remodeling complexes – facilitate this process by loosening the
ties between DNA and histones.
DNAmethylation is themost widely studied and widely under-
stood epigenetic mark and involves the covalent attachment of
a methyl (CH3) molecule to the cytosine of a CpG dinucleotide
(64, 65). In a minority of tissues and developmental time points,
CpG can also be modified in other ways. Of relevance to this
review, cytosines within CpGs can also be hydroxymethylated
within the brain (67). DNA methylation can occur throughout
the genome. The main regulatory regions of the genome, promot-
ers and enhancers often contain a high density of CpG and an
increase in methylation will usually correlate with a local, closed-
chromatin structure. For many gene promoters, this is associated
with silencing of the associated gene. For other regions, associ-
ations are context-dependent. For example, an open-chromatin
structure could facilitate the establishment of a repressor or
enhancer complex that could interact in cis or trans with a gene’s
promoter.
Both genetic and environmental variation, and an interac-
tion between the two, can influence epigenetic change (68, 69)
(Figure 1). For example, variation in local DNA sequence may
create or destroy the binding sequence for a sequence-specific
protein or RNA. In addition, genetic variation in a gene encoding
a protein with epigenetic function may result in aberrant activity
of this protein which may affect the activity of all the genes that
it regulates. Environmental factors are also known to influence
epigenetic marks prenatally and throughout life, include smoking
and stress (reviewed in Ref. (70, 71)). There are currently very few
replicated environmental epigenetic biomarkers.
Association, Causation, and Biomarkers
A statistically significant association of an epigenetic state with
a disorder after its onset could mean one of two things: that the
epigenetic statemediates the cause of, or results from, the disorder.
Although the former is a more attractive conclusion, evidence
must be accumulated that test this hypothesis. For example, if the
same epigenetic state were present prior to onset of symptoms,
ideally at birth, this would support the hypothesis. Furthermore,
if the environmental cause was linked with both epigenetic state
and the disease phenotype via an approach such as Mendelian
randomization (72, 73), this would also support the hypothesis.
It is also worth noting that epigenetic state, like all phenotypes,
is influenced by a combination of environmental, stochastic, and
genetic factors. Genetic factors predominate in about one fifth of
loci (69, 74). Mechanisms behind such an interaction include the
creation or destruction of a CpG site and alterations to the binding
affinity of sequence-specific binding factors. Approaches such as
Mendelian randomization, twin studies, and a focus on specific
genes and environments can help to quantitate the environmental
and genetic components of epigenetic state (73, 75–77). Factors
such as gene-environment interaction (69) should also not be
overlooked.
Epigenetic state can be used as a biomarker of disease risk,
diagnosis, prognosis, and response to treatments (reviewed in Ref.
(71)). Such biomarkers are already in use in the clinic for cancer; it
is only a matter of time before replicated biomarkers are used for
other diseases. The caveat for brain disorders, of course, is that
the key tissues mediating symptoms are not readily available for
biopsy. Therefore, readily available peripheral biomarkers, such as
those identified in blood and buccal cells, must serve as surrogates
for epigenetic changes, which have occurred in the brain. This is
discussed in the following section.
Epigenetics and Autism
Epigenetic modification is increasingly thought to play a role
in ASD, based on the findings discussed below. As mentioned
previously, genes that play a role in epigenetic pathways constitute
a sizable proportion of ASD candidate genes identified through
genetic screens (21, 78, 79). In addition, evidence is mounting
from human and animal studies that early life environment,
including in utero and during early postnatal life, may play a
role in ASD and other neurodevelopmental disorders (80, 81).
Most studies have focused on the epigenetic mark of DNA CpG
methylation. Effect sizes (mean methylation difference between
cases and controls) have been relatively low, mostly less than 0.1
(10%). As a rough guide considering levels of technical accuracy,
combined with the expected frequency of type 1 errors, >5%
effect size is considered a reasonable effect size and >10% effect
size would be a more ideal effect size with a higher likelihood of
biological plausibility.
Can Studying Epigenetics Shed Light on Mechanisms
and Biomarkers for ASD?
When we study disease-associated epigenetic marks such as DNA
methylation we are usually looking for two things: (1) clues to
the cause and mechanisms of a disorder and (2) biomarkers for
its risk, diagnosis, or prognosis (71). Clues to the causal factors
for a disease will come from cross-referencing with studies of the
effect of specific environmental components on the epigenome
from human or animal studies (71, 82). Clues to the mechanism
will be through detailed analysis of gene networks and pathways
and include systems-based approaches (82). As discussed ear-
lier, with the former, we need to be mindful of issues such as
reverse causation and genetic influences on epigenetics. With the
latter, although desirable, there is no strict rule that a biomarker
associates with a causal pathway.
Therefore with ASD, we have a number of options when
planning epigenetic studies. We can search for (1) signatures of
causative genetic or environmental factors; (2) clues to the phys-
iological mechanisms predisposing or resulting from the onset
of ASD; (3) biomarkers that will contribute toward a better pre-
diction of risk prior for ASD prior to diagnosis; (4) biomarkers
that will aid in diagnosis, including endophenotyping and (5)
biomarkers that may help in predicting symptom severity or
diversity. However, before we do this, there are a number of
considerations we need to make.
Tissues used to Study ASD-Associated Epigenetic
States
ASD is thought to be primarily a disorder of neurodevelopment
involving multiple regions of the brain including frontal, tem-
poral, and occipital lobe cortices and the cerebellum (83–85)
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(Figure 1). Post mortem studies of genome-wide expression and
DNA methylation have analyzed selected brain regions obtained
from biobanks. Despite notable efforts (86), brain biobanks are
rare, especially those with samples from children (87). As brain
tissue cannot be collected from live individuals, there are two
ways to address this issue: to establish more brain banks (87) and
to use readily obtainable peripheral tissues. The latter deserves
some discussion here. Each human tissue contains genomic regu-
latory regions in which epigenetic state is tissue-specific, regions
whose epigenetic state is shared with a subset of other tissues and
regions whose epigenetic state is common to all tissues (88–90).
The Human Epigenome Project (91) and other epigenomic data
repositories (e.g., Ref. (92)) can be used to distinguish between
each of these classes. However, only datasets obtained from sam-
ples from those with a specific disorder such as ASD can truly
determine between-tissue correlations for that specific disorder,
as disease state is likely to have some tissue specificity. Neverthe-
less, the physiological evidence, summarized above, of immune,
mitochondrial, and oxidative stress dysfunction in ASD imply
that blood and other easy-to-obtain peripheral tissues could be
studied in their own right. It has also been argued that environ-
mental components of disease may leave soma-wide footprints
on the epigenome (93). But can we go one step further in ASD?
Can peripheral tissues be used as proxies for epigenetic state in
the brain? This is a complex issue. High correlations have been
found between methylation levels of specific genes in blood and
brain regions in neurodevelopmental disorders and controls, for
example,COMT (inmultiple brain regions in schizophrenia (94)),
OXTR (in temporal cortex in ASD (95)) and HGC9 (in prefrontal
cortex, occipital cortex, corpus callosum in bipolar disorder (96)).
Furthermore, 50% of a set of schizophrenia candidate genes
and gene ontologies were found to be expressed in both PBLs
and prefrontal cortex (97) and there is a significant correlation
between DNA methylation in the blood, and cerebral cortex and
cerebellum (90).
Finally, genome-wide methylation profile in buccal epithelium
shows a higher similarity than blood in comparison with the brain
(98, 99), most likely because of a shared ectodermal origin. Thus,
if an environmental or stochastic event occurred in this lineage in
early embryogenesis, theoretically, effects could be seen in both
tissues. Epigenetic changes within buccal epithelium have also
been used as a proxy for the effects of early life environment
on the brain (100, 101). Peripheral tissues also have the advan-
tage that they can be sampled repeatedly and even retrospec-
tively, in the case of dried heel-prick blood spots taken just after
birth (102).
Methylation Analysis of ASD Candidate Genes
Although they are being superseded by genome-wide approaches
(Section “Epigenome-Wide Analysis of ASD”), candidate gene
approaches to the study of DNA methylation in ASD are still
valuable. They can afford a more detailed analysis of the epige-
netic state of a gene for which there is circumstantial evidence
for its dysregulation in ASD and allow comparison with RNA
and protein expression. Below, we review the small number of
genes identified by such approaches. Brain regions previously
shown to be associated with ASD are usually examined, such
as temporal cortex (responsible for processing auditory input,
high level visual processing, language comprehension, and emo-
tion association), cerebellum (coordinates voluntary movements,
posture, and balance), occipital lobe cortex (visual processing),
dorsolateral prefrontal cortex (working memory and executive
function including the regulation of thinking and action), ante-
rior prefrontal cortex (cognitive function), and anterior cingulate
cortex (error detection and conflict monitoring).
Oxytocin receptor
The oxytocin receptor (OXTR) is a G-protein coupled receptor
for the peptide hormone and neurotransmitter oxytocin. It plays
a role in anxiety, social memory and recognition, sexual and
aggressive behaviors, and maternal-offspring bonding. OXTR
has a score of 3 (“suggestive evidence”) in the SFARI ASD gene
database and a recent meta-analysis found significant associations
of four OXTR SNPs with ASD (103). The first evidence of an
association between OXTR methylation and ASD came from a
study of two siblings with ASD, only one of which had an OXTR
deletion (95). Compared to his father, the sibling without the
OXTR deletion had differential DNA methylation in peripheral
blood leucocytes (PBLs) in a region of the OXTR promoter
previously shown to regulate expression. The highest difference
in methylation at a single CpG was 37.5%. Further analysis of
peripheral blood mononuclear cells (PBMCs) in 20 sex-matched
ASD cases and controls showed 23% higher DNA methylation
in ASD at specific CpGs. When males and females were analyzed
separately, the magnitude of these differences was much larger
in males (39% higher in ASD), underlining the need to test for
sex effects in such studies. The study went further by comparing
levels of DNA methylation in temporal cortex from ten ASD
cases and age- and sex-matched controls. Similar sex-specific
differences were found in temporal cortex and PBLs, with up
to 41.6% higher methylation at specific CpG sites in males with
ASD (95). Higher methylation levels in males correlated with
lower OXTR expression in temporal cortex. Caution must be
taken with interpretation of this data because blood and brain
samples did not come from the same individuals. Linking DNA
methylation with a particular ASD-associated endophenotype,
Jack and colleagues found a strong correlation between OXTR
promoter methylation in PBMCs and perception of animacy
(purposeful movement) of an inanimate object, with correlated
neural responses in two brain regions measured by functional
magnetic resonance imaging (fMRI) (104). The inter-individual
differences in DNAmethylation were around 30%, well within the
range of biological plausibility. Associations have also been found
between DNA methylation of OXTR and traits with phenotypes
overlapping with ASD, such as social anxiety disorder (105), and
callous, unemotional traits (106, 107), reviewed in Ref. (108).
Glutamate decarboxylase 1
Glutamate decarboxylase 1 (GAD1, also known as GAD67)
encodes an enzyme that catalyzes the production of GABA
(gamma-aminobutyric acid), the chief inhibitory neurotransmit-
ter, from glutamate. There is little evidence linking genetic vari-
ation in GAD1 with ASD. It has an entry but no score in the
SFARI ASD gene database (13). However,GAD1 expression is dis-
rupted in Purkinje neurons in the cerebellum from ASD patients
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(109, 110). Furthermore, complete loss (111) or haploinsuffi-
ciency (112) of Gad1 in mice leads to deficits in learning and
social behavior. A recent study found an increase in DNA hydrox-
ymethylation (of ~3%) at the GAD1 promoter in cerebella from
ASD patients using two different methods (113). This change was
accompanied by increased binding of the methyl CpG binding
protein 2 (MeCP2), which plays a role in gene silencing. This
illustrates that a gene may be associated with ASD through epi-
genetic, but not genetic, change. This is important because Gad1
expression was reduced by prenatal exposure to the anticonvul-
sant valproate in rats (114) and by a prenatal immune challenge
in mice (115, 116). Both types of exposures have been linked
with an elevated risk for ASD (117, 118). Taken together, current
evidence suggests that GAD1 is a good candidate for a gene that
could be epigenetically mis-regulated by in utero environment,
predisposing to ASD.
Engrailed-2
Engrailed-2 (EN2), which encodes a homeodomain-containing
protein, has been implicated in the control of pattern formation
during neurodevelopment (119). EN2 has a score of 4 (“mini-
mal evidence”) in the SFARI ASD gene database (13). The EN2
promoter had increased levels of DNA methylation in ASD cere-
bella compared to asymptomatic controls (120). Two different
techniques showed significant differences of 10–20%methylation.
A similar relationship was later found with hydroxymethylation
(121). DNA methylation was also positively correlated with levels
of EN2 RNA and protein levels and negatively correlated with
levels of repressive epigenetic marks in the same tissue (120, 121).
Reelin
Reelin (RELN) is a secreted extracellular matrix glycoprotein
involved in neuronal migration and positioning in the developing
brain and modulates synaptic plasticity in adult brain. It has a
score of 2 (“strong candidate”) in the SFARI ASD gene database
(13). Similar to GAD1, a recent study found an increase in levels
of DNA methylation and a decrease in hydoxymethylation at the
RELN promoter in cerebella from ASD patients, accompanied
by an increased binding of MeCP2 (113). Lower levels of RELN
mRNAwere found in frontal cortex and cerebellum in individuals
with ASD (113, 122) and lower levels of RELN protein have
been found in the brain (122, 123) and plasma (124) of those
with ASD.
MECP2
MECP2 plays a role in gene silencing. Mutations inMECP2 cause
Rett syndrome, which has overlapping phenotypes with ASD
(125). It is referred to in the SFARI ASD gene database as a
“syndromic gene” (13). Abnormal levels ofMECP2 transcript and
protein together with atypical splice variants have been found in
frontal cortex from patients with ASD (126). In a follow-up study,
the same group found lower levels ofMECP2 expression in frontal
cortex in 11/14 ASD cases compared to age-matched controls
and an increased level (up to 12%) of DNA methylation at the
MECP2 promoter inmales, which negatively correlatedwith levels
ofMECP2 protein (127). In a third study, the investigators focused
on a transition region of theMECP2 promoter, separating regions
of female-specific from sex-independent methylation in frontal
cortex (128). DNA from male ASD patients showed increased
levels of DNA methylation (~10%) while females showed some
abnormal methylation. No evidence was found for general defects
in X inactivation in blood and brain prompting the conclusion
that aberrant MECP2 methylation in ASD brain DNA is due
to locus-specific rather than global X chromosome methylation
changes. Of note, a mouse model of ASD found an effect of
maternal immune activation on Mecp2 methylation (129), again
showing that ASD-associated changes in methylation can arise
from adverse in utero environments.
Summary of candidate gene analyses
The evidence for the association of each of the above five candidate
genes with ASD is summarized in Table 3. All candidates have
TABLE 3 | Summary of evidence for potential ASD-specific methylation biomarkers.
Gene Genetic
evidence
Methylation
reference
Diagnostic
method
Tissue Samplesa Largest
effect sizeb
Expression Protein Other data
OXTR Weak (95) DSM-IV, ADI-R PBLs 20/20 +23% No No Endophenotyped
10/10c +38.9%
Temporal cortex 10/10c +41.6%c yes No
GAD1 Weak (113) Not given Cerebellum 10/10 +3%e Yesf No Animal models,
MECP2 binding
EN2 Minimal (120) DSM-IV Cerebral cortex 13/13 +10–20%g Yes Yes
RELN Strong (113) Not given Cerebellum 10/10 Not quantifiable Yes Yes MECP2 binding
MECP2 Syndromic (127, 128) ADI-R, ADOS Frontal cortex 14/14 +12%, +10%h Yes Yes Animal model
For abbreviations and references see the main text.
aCases/controls.
b% methylation difference, cases minus controls.
cMales only.
dMethylation correlated to endophenotype.
eHydoxymethylation only.
f In Purkinje neurons and cerebellum.
gMethylation and hydroxymethylation.
hTwo separate sets of MECP2 CpG sites regions measured.
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evidence of association with ASD beyond genetics and DNA
methylation. Plausibility is increased by effect sizes>10% (OXTR,
EN2, MECP2), from associations with expression (all genes), pro-
tein levels (EN2, RELN, MECP2). For all candidates, methylation
differences were found in different brain regions, but only OXTR
has shown differences in a peripheral tissue (blood). All four
candidates are worthy of further attempts at replication, ideally in
multiple brain regions and multiple tissues.
Epigenome-Wide Analysis of ASD
Seven recent studies have gone beyond candidate genes to study
levels of DNA methylation on a genome-wide scale, commonly
termed as epigenome-wide association studies (EWAS) (130–
136). By “genome-wide,” we refer tomethods that query epigenetic
state on all human chromosomes, although not necessarily at
every CpG in the genome. Below, we briefly review the different
EWAS methods used in these epigenetic studies and discuss the
major issues associated with their interpretation.
Epigenome-wide association studies methods fall into two
major classes: those based on the affinity of a molecule for methy-
lated cytosine and those based on the sequence difference result-
ing from conversion of only non-methylated cytosine to uracil
using sodium bisulfite (137). Each method comes with its own
strengths and weaknesses. Affinity-based methods analyze the
whole genome but have a bias toward CG-rich regions, have a rel-
atively low resolution (not individual nucleotides) and are consid-
ered only semi-quantitative. The fractions of the (epi)genome they
isolate can be analyzed using microarrays of by high-throughput
sequencing. Examples reviewed below include methylated CpG
island recovery assay (MIRA) (134, 138, 139) and methylated
DNA immunoprecipitation (MeDIP) (135, 140). The most com-
monly used array-based method is the Infinium BeadChip array
which targets specific CpG sites using bead attached probes com-
plementary to specific genomic regions which assay specific CpGs
at one end of the probe (141). HM27 arrays, now no longer
available, contain probes for 27,578 CpGs covering 14,469 genes,
with enrichment for CpG islands and proximal promoter regions
and for genes associated with cancer (141–144). HM450 (also
known as “450K”) arrays contain probes for 482,421 (or 1.7%)
of the 28 million CpG sites genome-wide. Probes include most
of those on HM27 arrays and an additional set targeted to those
regions of the genome judged to be of regulatory importance by
an expert panel. Such regions include promoters, enhancers, CpG
island “shores” (2 kb either side of CpG islands) and “shelves”
(2 kb either side of shores) together with intragenic and intergenic
regions. An advantage of HM450 arrays is that they are considered
quantitative and their main disadvantage is their low genomic
coverage, especially in intergenic regions. This means that they
could miss some differentially methylated regions (DMRs) picked
up by affinity-based methods. Nevertheless, they are the current
method of choice for most genome-wide studies of DNA methy-
lation in humans mainly because of their relatively low cost and
their quantitative nature. The ultimate resolution for genome-
wide studies is bisulfite sequencing of the entire genome, which
is currently cost-prohibitive for most studies, although methods
have been developed to sequence functionally important regions
of the genome (reviewed in Ref. (137)).
There are a number of “best practices” when it comes to
planning, conducting, and analyzing genome-wide methylation
analysis that will assist in the interpretation of the studies reviewed
below (reviewed in Refs. (137, 145–148)). First, false positives
should be minimized by adjusting for genome-wide multiple test-
ing and the use of a false discovery rate (FDR) cut-off of adjusted
p< 0.05 or <0.1. False positive rate can be further reduced by
selecting only those probes or regions clustered within genomic
space; this is especially important for HM450 arrays that rely on
the hybridization of single probes within a given region. Further
recommended options to decrease the false positive rate include
validation of top differentially methylated probes (DMPs) or
DMRs using an independent, locus-specificmethod (149–151) on
the same samples and using a cut-off for effect size as mentioned
above.
Even when these conditions are satisfied, findings need to be
replicated in independent cohorts. While the use of a differ-
ent method of genome-wide analysis is desirable, comparison
between different platforms can be difficult for reasons includ-
ing differences in genomic coverage and resolution. One further
consideration is the functional relevance of disease-associated
differences in DNAmethylation. The “best case” scenario is when
methylation correlates with expression of a nearby gene that has
relevance for the specific disorder, but such associations are often
not found or not looked for. Having said that, as discussed ear-
lier, functional relevance is not an absolute requirement for an
epigenetic biomarker.
At the design stage, accurate phenotyping and study power
are important issues to consider. As with other “omics” studies,
bigger is usually better, although the proportion of variance in
phenotype explained by single epigenetic variants appears to be
much larger than genetic variants (e.g., Ref. (152, 153)). Power
has been difficult to calculate in genome-wide studies of DNA
methylation because every CpG or region has a different between-
subject variance. Typical published sample sizes have been grow-
ing from two to three and even four digit numbers over the
past few years and again, necessary sample size is dependent on
effect size (137). Twin studies, recommended as the place to start
for epigenome-wide analysis, can withstand smaller sample sizes
because within-pair analysis controls for sex, age, parents, family
environment, and genetics (more in identical than fraternal twins)
(75, 137).
At the analysis stage, potential confounders, such as age, sex,
genetic factors such as ethnicity, biological (e.g., heterogeneity of
tissues such as blood), and technical variation, need to be queried.
Issues of cause vs effect and which tissue to analyze have already
been discussed.
Below we review, to our knowledge, all the genome-wide stud-
ies of DNAmethylation conducted on ASD samples (summarized
in Table 4), covering first the studies on brain tissue and then
peripheral tissue.
Genome-wide analyses of DNA methylation in the brain
in ASD
Using DNA from the cerebellar cortex and occipital cortex from
nine men with ASD (diagnosed using DSM-IV, ADOS, and/or
ADI-R) and nine age-matched controls, Ginsberg and colleagues
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TABLE 4 | Summary of genome-wide studies of methylation in ASD.
Reference Samplesa Tissue Participant
age (years)
Diagnostic
method
Method of
analysis
DMR/DMP
analysisb
Effect
size
cut off c
Adjustment
for multiple
testing
Validationd Expression
datae
(131) 9/9f Occipital cortex 1–60 DSM-IV, ADOS,
and/or ADI-R
HM27 DMP No Yes Nog Yes
Cerebellar
hemispheric cortex
(132) 12/21 Prefrontal cortex 17–35 ADI-R and/or
ADOS
HM450 DMR No Yes No No
16/21 Temporal cortex 21–40 Yesh
13/21 Cerebellum 14–17 Noi
(133) 11/11 Anterior cingulate
gyrus
16–51 ADI-R HM450 DMP >5%
difference
Yes Yes Yes
12/12 Prefrontal cortex
(134) 3f, 10 LCL 2–19 ADI-R MIRA DMR No Yes Yes Yes
(135) 5/5 PBLs 6–12 DSM-IV, MINI
instrument
MeDIP DMR >1.5-fold
change
No Yes Yes
(136) 6j PBLs 15 CAST HM27 DMP No No No No
16/22 Yes
6/10k No
50l, m No
(130) 47/48 Buccals 1–28 Not stated HM450 DMR No Unclearn Yes No
For abbreviations see the main text.
aCases/controls.
bAnalysis based on probes (single CpGs) or regions (groups of CpGs).
cUse of a threshold of minimal effect size (% methylation).
dUsing a locus-specific method.
eAttempted to correlate methylation with expression at DMRs.
fOnly males.
gValidation process was done but findings were not validated.
hSome findings were validated in temporal cortex and cerebellum samples.
iFindings were not validated in the replication study.
jASD-discordant MZ twins.
kSporadic ASD/familial ASD.
lFor regression of CAST scores and methylation.
mTotal number of MZ twin pairs.
nDMR identification was confirmed by re-running “bump-hunting” four times.
used HM27 arrays to identify ASD-specific probes at an FDR
of 0.05 (131). No significant DMPs or differentially methylated
gene networks were found. An array-based genome-wide gene
expression analysis produced 876 genes differentially expressed
between autistic and control brains at an FDR of 0.05. Ontol-
ogy analysis showed down-regulation of genes involved with
mitochondrial oxidative phosphorylation and protein transla-
tion. The former but not the latter have been identified in
physiological studies of ASD. The authors also found differ-
ential expression of genes involved in synapse formation and
other brain functions, some of which had been discovered using
genetic analysis. Breaking down ASD into sub-phenotypes, two
gene modules were significantly associated with social inter-
action and one gene module with stereotyped and repetitive
behavior. Immune response was a common feature of these
modules.
Ladd-Acosta and colleagues analyzed DNA methylation, using
Infinium HM450 arrays, in the dorsolateral prefrontal cortex
(n= 12), temporal cortex (n= 16), and cerebellum (n= 13) from
individuals with ASD, diagnosed using ADI-R and/or ADOS, and
21 control brains matched for age, sex, and post-mortem interval
(132). After removal of SNP-containing probes, they applied a
further cut-off for those probes that were clustered in genomic
space (adjacent probes within <500 bp). FDR< 0.1 was used to
produce over 1000 DMRs for each tissue.
The authors focused on the three DMRs with the lowest
adjusted p-values. The first, found in temporal cortex, waswithin a
possible bidirectional promoter for the tetraspanin 32 (TSPAN32)
gene and the uncharacterized transcript C11orf21 on chromo-
some 11. This DMR extended into the body of C11orf21, spanned
1.5 kb and 26 HM450 probe CpGs and was on average 6.6%
less methylated in ASD. “Replication,” performed using HM450
data from specific probe CpGs on the other two tissues, showed
evidence for this DMR in cerebral cortex. TSPAN32 is a tumor
suppressor and is involved in hematopoietic cell function and cel-
lular immunity (154). TSPAN32 and C11orf21 lie within a region
of chromosome 11 rich in imprinted genes including IGF2 and
H19. However, current data suggest that TSAPN32 is biallelically
expressed in most tissues and species, with the exception of day
9.5 placenta in mouse (155) and human placental trophoblasts
(156), where it is expressed from the maternal allele only. No
studies of TSPAN32 or C11orf21 imprinting or function have
been performed in brain tissue. Outside the placenta, the brain
is one of the most frequently imprinted, but least-studied, tissues
(157). Imprinted loci are particularly susceptible to environmental
influence due to their haploid expression.
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A second temporal cortex DMR was located in the 30 untrans-
lated region (30UTR) of the proline-rich transmembrane protein 1
(PRRT1) gene close to theMHC region on human chromosome 6.
This DMP encompassed a few hundred kb, 33 HM450 probes and
was on average 7.8% lessmethylated inASDbrains. Fourteen indi-
vidual probes were replicated as above, in prefrontal cortex and
cerebellum. Little is known about PRRT1 function in mammals.
A third temporal cortex DMR was located in a region ~3.5 kb
upstream of the zinc finger gene ZFP57, also close to the MHC
region on chromosome 6. This DMR also encompassed a few
hundred bp, ~12 HM450 probe CpGs and was, on average, 13.9%
moremethylated in ASD cases. Replication showedDMRs in tem-
poral cortex and cerebellum in females only. ZFP57 is a transcrip-
tion factor that binds preferentially to methylated DNA within
imprinted DMRs and in doing so, maintains DNA methylation
and genomic imprinting during development (158). The DMR
also maps to a known regulatory element of ZFP57 (159) and the
same region was also the strongest DMR in a study of the effects
of maternal folate intake on cells from the innate and adaptive
immune systems (160). As folate intake andmetabolismhave been
implicated, but not proven, as a potential contributor to ASD
risk (161–163), this gene could be a possible mediator between
environment, genetics, and epigenetics in ASD.
A further DMRwas found in cerebellum using the abovemeth-
ods within a 1 kb region around the promoter region of the succi-
nate dehydrogenase complex subunit A flavoprotein pseudogene
3 (SDHAP3) on chromosome 5. ThisDMPcomprised ~10HM450
probe CpGs and was, on average, 15.8% more methylated in ASD
cases. An attempt to replicate these findings in other brain tissues
showed no significant DMPs, although a general trend toward a
similarmagnitude of DNAmethylationwas seen. Unlike the other
ASDDMPs, evidence was found for a causal relationship between
local copy number variation andDNAmethylation at the SDHAP3
DMR, but the authors argued that this still implicated the gene in
the etiology ofASD. Little is known about the function of SDHAP3
other than it has coding and non-coding transcripts. Mutations in
other succinate dehydrogenase (electron transport chainComplex
II) components cause a number of human metabolic disorders
(164), possibly linking this DMR with mitochondrial dysfunction
seen in ASD.
Ladd-Acosta and colleagues also investigated the possibility
that differences in cellular heterogeneity betweenASDand control
brains influenced methylation levels in their data (132). Using
published data on cell type-specific methylation in the brain, the
authors found no evidence for an effect of cellular heterogeneity
on methylation levels within their DMRs. The authors did not
perform pathway analysis of their DMRs.
Nardone and colleagues analyzed DNAmethylation, also using
Infinium HM450 arrays, in the anterior cingulate gyrus and
prefrontal cortex from 11 and 12 matched ASD (diagnosed
using ADI-R) and control pairs respectively (133). They selected
DMPs using an FDR <0.05, and a cut-off of at least 5% differ-
ence in methylation between cases and controls. This analysis
yielded >5000 DMPs for each tissue. Both sets of DMPs were
enriched in CpG island shelves, intergenic regions and gene bod-
ies and depleted in CpG islands and promoters. Such patterns
are found in regions more likely to change over time during
prenatal development and aging ((165) and references therein)
and including regions whose methylation changes significantly
during the development of the prefrontal cortex in mice and
humans (166). In addition, the two brain regions studied were sig-
nificantly more epigenetically similar in samples from ASD than
those from controls. The authors concluded that these findings
were the manifestation of a disruption to methylation-associated
neurodevelopment. Gene pathway analysis showed enrichment in
DMP-associated genes for immune-related biological processes
such as leukocyte migration, cytokine-mediated signaling path-
ways and inflammatory response and to a lesser extent, synaptic
transmission. DMPs showed little overlap with the SFARI gene
database but did overlap with the dataset of ASD-associated dif-
ferences in expression from an adjacent region of the dorsolateral
prefrontal cortex (BA9 compared to BA10 studied byNardone and
colleagues) from an independent transcriptomic analysis (62). In
addition, genes associated with DMPs that had higher levels of
DNA methylation in ASD samples overlapped significantly with
genes that were under-expressed in ASD. The authors suggested
that the dearth of immune-related genes in genetic studies of ASD
implied that such genes were more likely to be influenced by
epigenetic than by genetic change. This agrees with the findings of
Ginsberg and colleagues above (131). The authors observed that
many of the immune-related genes they identified are also associ-
ated withmicroglial function.Microglia act asmacrophages in the
brain,with roles in synaptic pruning and in guiding cell fate during
brain development (167). The authors ranked gene-associated
DMPs by the number of DMPs associated with each gene (as
opposed to clustering of probes in absolute genomic space). None
of the highest-ranked genes had previously been associated with
genetic studies of ASD. The highest-ranked cluster of CpGs (20
probes, each one located within 500 bp of adjacent probe CpGs)
lay in almost exactly the same region of TSPAN32/C11orf21 as
that identified by Ladd-Acosta and colleagues (132). Like the
former study, probes were on average 8% less methylated in ASD
brains. Seven of these probes were validated using pyrosequenc-
ing. Of note, three prefrontal cortex-specific DMPs (average 9%
less methylation in ASD), all within 1 kb at the 30UTR of the
PRRT1 gene coincided with one of the top four DMRs identified
previously in prefrontal cortex and cerebellum (132). One of these
DMPswas also found in anterior cingulate gyrus. A single anterior
cingulate cortex DMPwas also found in ZFP57 – the same gene as
that associated with a previously identified DMR (132), although
in a different location within the gene.
Genome-wide analysis of DNA methylation in peripheral
tissues in ASD
The first study of genome-wide DNA methylation in ASD on
peripheral tissue analyzed DNA from B-cell derived lymphoblas-
toid cell lines (LCLs) from three pairs of twins discordant for
severity of ASD (134). Although one twin from each pair was
diagnosed with ASD using ADI-R, all co-twins had ASD-like
symptoms, albeit not severe enough to meet diagnostic criteria.
Investigators used the MIRA method of affinity capture com-
bined with CpG island microarrays containing ~12,000 CpG
island promoters. Using an FDR cut-off of <0.1, 73 CpG islands
were significantly differentially methylated within all three pairs.
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ASD-associated genes were enriched for genes involved in neu-
rological disease, nervous system development/function, cellular
assembly/function and embryonic function. Treating both twins
from each pair as “broadly autistic” and comparing both with
unaffected siblings resulted in 201 differentially methylated CpG
islands. ASD-associated networks included nervous system devel-
opment/function and neurological disease, as for the first analysis,
together with control of transcription, and cell death. All further
analyses were performed with this dataset. Cross-referencing with
genes differentially expressed in the same samples (53) showed
that all but one of the genes had high inverse correlations between
methylation and expression. Network analysis of these genes
highlighted the same pathways as those found with methylation
alone, with the addition of inflammation, digestion and steroid
biosynthesis (134). In the promoter of the B-cell CLL/lymphoma
2 (BCL2) gene, similar levels of methylation were found in undi-
agnosed twins and siblings (11.4 and 9.5%, respectively, validated
using bisulfite sequencing), with ASD twins having around 15%
higher methylation than the two types of controls. In the retinoic
acid related orphan receptor alpha (RORA) promoter, qualitative
analysis, using methylation-specific PCR, confirmed higher levels
of DNA methylation in twins with ASD compared to all controls.
Investigators then presented evidence for a role of DNA methy-
lation in the expression of both BCL2 and RORA and that levels
of RORA protein are reduced in cerebellum and frontal cortex in
ASD. RORA is a nuclear steroid receptor linked to transcriptional
activation of genes involved with neurodevelopment, circadian
rhythm, and protects against the effects of inflammation and stress
(168). It had not previously been associated with ASD, although
other studies have suggested a role of RORA in the environmental
causes and the sex bias observed in ASD (169). BCL2 is a major
player in cell death pathways and reduced levels of expression have
been found in lymphoblasts (170) and frontal cortex (171) of those
with ASD compared to controls.
Wang and colleagues analyzedDNAmethylation, usingMeDIP
and promoter arrays, in PBLs from five children with DSM-IV-
diagnosed ASD and five age- and sex-matched controls (135).
Over 200 genes were significantly differentially methylated using
a combination of an unadjusted p< 0.05 and at least 1.5-fold
difference between ASD cases and controls. Thirteen of these
genes were significantly differentially methylated in all five pairs.
Four of these genes were selected for locus-specific validation
using bisulfite sequencing but only enolase 2 (ENO2, also known
as neuron-specific enolase and expressed in developing neurons
(172)) was validated. This shows the importance of validation to
decrease Type 1 errors. ENO2 promoter methylation was 28.1%
higher in ASD cases compared to controls. Of a total of 131
additional case-control pairs, only 19 (14.5%) of pairs showed dif-
ferences of a similar magnitude, which were negatively correlated
with ENO2 expression. Therefore, with a larger sample size, ENO2
did not replicate as a potential ASD-specific biomarker. No other
associations between ASD and ENO2 have been found previously
or since. It is also worth noting that the promoter of brain-derived
neurotrophic factor (BDNF) was also significantly differentially
methylated in this study, withmethylation levels differing between
four out of five case-control pairs. Multiple studies have identified
significantly different levels of BDNF protein in the blood of those
with ASD compared to controls (173–177). However, no other
studies have identified BDNF as differentially methylated in ASD.
Using PBLs from 50 pairs of monozygotic (MZ) twins, Wong
and colleagues used Infinium HM27 arrays to identify spe-
cific differentially methylated CpG sites associated with ASD
(136). Although authors referred to their differentially methylated
probes as “DMRs,” strictly speaking, they were DMPs and this is
howwewill refer to themhere. The authors used twomajor analyt-
ical approaches to identifying ASD-associated DMPs: within-pair
and case-control analysis. CAST scores of >15/31 were used to
assess whether a child was at risk of ASD.
In the within-pair analysis of six pairs of ASD-discordant MZ
twins, a ranked list of top 50 DMPs were generated from six
MZ twin pairs by combining significance (t-test unadjusted p-
value) and effect size (methylation difference between cases and
controls). The topDMPwas located in the promoter of the nuclear
transcription factor Y gamma (NFYC) gene with ASD cases show-
ing an average 8% higher methylated compared to control co-
twins. Other top co-twin DMPs included probes associated with
the dual-specificity phosphatase 2 (DUSP2) gene, with 5% lower
methylation on average inASD co-twins. This gene had previously
been identified as a target of microRNAs mis-regulated in ASD
(49). In a secondwithin-pair analysis, this time analyzing each pair
separately, the authors found several DMPs that were common
across two or more ASD-discordant twin pairs. These included
the heme-containing peroxidase PXDN gene, with 24% higher
methylation on average in the ASD-co-twin in two pairs, and the
unannotated transcript C110rf1, with 29% higher methylation on
average in the ASD-co-twin in two pairs.
A case-control analysis (n= 16 and 22, respectively) found
DMPs within an intron of the unannotated transcript MGC3207
(on average, 24% less methylated in ASD cases), within the puta-
tive promoter of the olfactory receptor gene OR2L13 (on average,
18% more methylated in ASD cases) and within an intron of
the transcript of unknown function FAM181A (also known as
C14orf152; on average, 16% less methylated in ASD cases). Find-
ings from the first two probes were validated by bisulfite pyrose-
quencing. The authors expressed caution with interpretation,
noting that effects of local DNA sequence could be influencing
methylation levels at these two probes, but ruled this unlikely at
MGC3207 because they could find no obvious local polymorphic
sequence variant. Of note, the OR2L13 expression is dysregulated
in Parkinson’s disease (178). FAM181A was hypermethylated in
peripheral blood from adults with asthma (179) and in peripheral
blood from infants exposed to asthma during pregnancy (180). In
one study, fathers with asthmawere at higher risk of having a child
with ASD (181).
To identify any epigenetic differences between sporadic (one
twin of each pair with ASD, n= 6) and familial (both twins in
each pair with ASD, n= 10), comparisons were made of ASD
individuals between the two groups. The top DMP from this
comparison was located upstream of the transcript of unknown
function C19orf33 (on average, 12% less methylated in indi-
viduals with sporadic ASD). Other significant subtype-specific
DMPs were located within the methyl-binding domain gene
MBD4, the autism susceptibility candidate 2 gene AUTS2, and
the microtubule-associated protein gene MAP2, all previously
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associated with ASD (13). Both AUTS2 and MAP2 play a role in
neurodevelopment.
Wong and colleagues also analyzed probes associated with the
autistic trait scores of social, repetitive behaviors and interests,
and communication. DNAmethylation atmultiple CpG sites were
found to be correlated with CAST scores, including one in the
putative promoter of the neurexin 1 (NRXN1) gene previously
associated with ASD (13).
In addition, a small number of genes appeared in more than
one of the above analysis. For example,NFYC and transmembrane
phosphoprotein PTPRCAP genes contained top DMPs in both
within-pair and case-control analyses.
Berko and colleagues analyzedDNAmethylation usingHM450
arrays and DNA from buccal epithelium from 47 cases of ASD
(diagnostic tool not described) and 48 unaffected controls (130).
Care was taken to exclude probes associated with known CNVs
or SNVs. The authors also used an analytical approach which
incorporated information on clustering of potential DMPs and
adjustment for technical (e.g., microarray chip) and biological
(e.g., age, sex) variation (182). This approach yielded nine ASD-
specific DMRs, whose associated genes were all also expressed in
the brain and six from nine associated with synaptic transmis-
sion, although none were previously identified as ASD-specific
from genetic studies (13). One DMR, however, present within
the OR2L13 putative gene promoter, contained the ASD-specific
DMP identified in the case-control analysis of peripheral blood
(136). It was on average 8% lower in individuals with ASD but the
direction of effect was opposite to the former study. OR2L13 is
upregulated in frontal cortex and downregulated in frontal cortex
from individuals with ASD (62). DMRs atOR2L13 and FAM134B
were validated using bisulfite high-throughput sequencing. No
significantly differentially methylated gene networks were iden-
tified. However, from their DMP data, the authors concluded that
the same pathway, synaptic transmission, could be affected by
genetic and epigenetic change inASD and stressed the importance
of combined genetic and epigenetic analysis.
Strengths and Weaknesses of the
Genome-Wide Studies of DNA Methylation
in ASD
First, the low numbers of cases and controls in all studies are
striking and way below the ideal of >100. Replication of poten-
tial ASD-specific methylation biomarkers must be attempted in
much larger sample numbers. Next, an extremely diverse vari-
ety of biological samples were used in the different studies.
Although the identification of the same gene in different tis-
sues, methods and studies (namely OR2L13, PRRT1, ZFP57, and
TSPAN32/C11orf21) suggest potential ASD-specific methylation
biomarkers worthy of replication, this replication would also
need to be within-tissue in future studies. Age of participants
is also an issue of concern because it is possible that ASD-
discordant pairs may grow more epigenetically discordant with
time, meaning that DMPs/DMRs could either be age-related
stochastic/environmental epigenetic changes or a simple effect
of autism rather than on the causal pathway. Variation in the
method of ASD diagnosis is also a major issue because each set
of DMPs/DMRs is, to a large extent, specific for each diagnostic
tool. Future studies should attempt to use only the most reliable
method, i.e., DSM-V (183). Heterogeneity of analysis platform
also clouds comparison between studies, for example some CpGs
or regions will not be represented on all platforms. In addition,
some methods (e.g., HM27, HM450) use probes, whereas oth-
ers (MIRA, MeDIP) work with regions. Again, one or two core
platforms, e.g., array and sequence-based to control for method-
specific biases, would be ideal for all future studies. An ideal
genome-wide methylation analysis would involve a focus on con-
tiguous regions rather than single CpGs (probes) or annotated
genes (131), adjustment for multiple testing, the use of a minimal
effect size cut-off, validation with an independent method in the
same samples or different samples from the same study population
and replication in independent cohorts. Asmentioned above, four
genes fulfill the final criteria, but no one study fulfils all. Finally,
only four studies looked for a relationship between methylation
and expression for top DMPs/DMRs (131–135). In conclusion,
although these studies identify a small number of potential ASD-
specific biomarkers requiring replication, future studies should
focus on larger numbers, harmonization of ASD diagnosis, vali-
dation, replication and other “best practices” such as adjustment
for multiple testing.
Synthesis
Despite their weaknesses, the seven recent studies of DNAmethy-
lation inASDprovide some useful insights into its etiology. Firstly,
a small number of replicated, potential methylation biomarkers
for ASD have emerged. For PRRT1, lower methylation ( 9%) in
a DMR 30 UTR in temporal cortex and cerebellum (132) was
replicated by lower methylation ( 7.8%) in the same region in
prefrontal cortex using the same platform (133). For a region
upstream of ZFP57, higher methylation (+8.9%) in a DMR
in temporal cortex (132) was replicated by higher methylation
(+9.4%) in cingulate cortex also using the same platform (133).
For TSPAN32/C11orf21, lower methylation ( 6.6%) in a DMR
in a putative bidirectional promoter and gene body in temporal
and cerebral cortex (132) was replicated with lower methylation
( 8%) in anterior cingulate gyrus and prefrontal cortex using
the same platform (133). For OR2L13, the situation is different.
Significantly higher promoter methylation (+18% at a DMP in
PBLs) was seen in one study (136), whereas significantly lower
methylation ( 8% for the same probe within a DMR in buccal
epithelium) was seen using a similar platform (130). Citing an
additional study that found opposite directions of effect for ASD-
associated expression of OR2L13 (62), the latter study suggested
that this gene may be especially epigenetically labile (130).
Two differentially methylated gene pathways were found in
multiple studies: neurodevelopment and immune and inflamma-
tory response (132, 134). The former were also found in genomic
and transcriptomic studies of ASD and the latter mainly in tran-
scriptomic and physiological studies. Of note, though, a recently
compiled network of genes associated with a variety of genetic
changes in ASD-affected individuals includes the complement
genesC1Q andC3 (184), which are also prefrontal cortexDMPs in
the methylation study of Nardone and colleagues (133). Although
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there have been a greater number of epigenomic studies than
transcriptomic studies of ASD, it is possible that immune-related
pathways aremore likely to be affected by the environment and/or
stochastic processes influencing epigenetic state (132). Specific
symptoms of immune dysfunction in ASD include neuroinflam-
mation, presence of autoantibodies and enhanced T cell, natural
killer cell andmonocyte immune responses (51), and an increased
frequency of allergies and autoimmune disorders together (185).
Microglia are the major immune cell type in the brain and play
major roles in neurodevelopment and synaptic function (186).
Microglia may provide a mechanistic contribution to a proposed
environmental cause of ASD, maternal immune activation (3).
Maternal infection has also been involved in gene–environment
interaction in ASD (187) and microglial activation has been
observed in post-mortem brains from children with ASD (188).
The RORA gene, found to be epigenetically different in ASD (134)
also represents a gene with dual roles in immune function and
neurodevelopment. Time will tell whether there are more path-
ways, such as oxidative phosphorylation and protein translation
(131), that are shown to be consistently preferentially associated
with epigenetic change in ASD and whether these are related to
altered physiology in ASD.
To summarize, we present a possible model of the findings
reviewed above. Figure 1 illustrates how genetic and epigenetic
loads combine and interact to cross a threshold, over which,
neurodevelopment, immune function and other pathways are
compromised, neurodevelopmental buffering is ineffective and
decanalization occurs. These dysfunctions are proposed to result
in ASD, with individual phenotypes differing in a manner depen-
dent on the specific gene networks compromised and in the timing
and nature of each specific environment-induced set of epigenetic
changes (i.e., unique ASD epigenomes).
Future Directions
The five candidate genes whose methylation correlates with a
diagnosis of ASD and for which there is additional evidence of
involvement with ASD warrant attempts at replication, ideally
in larger sample numbers and multiple tissues. Priority should
be given to those with the largest effect sizes (OXTR, EN2 and
MECP2). In addition, all four DMPs/DMRs identified by two
independent genome-wide studies also warrant such attempts
at replication. This needs to be done before firm conclusions
can be made about the association of these genes with causes
and mechanisms of ASD (all tissues) and their suitability as
ASD biomarkers (peripheral tissues). It is pertinent that all ASD
DMRs identified in buccal epithelium (130) were also expressed
in the brain, as were many of the ASD DMPs identified in blood
(136).
Studies of genome-wide DNA methylation in ASD need to be
larger, phenotyping needs to be standardized between studies,
analysis platforms need to move toward true genomic coverage,
genetic variation needs to be taken into account, and analytical
methods need to be standardized to include differentially methy-
lated probes and regions. In addition, with sufficient sample size,
endophenotypes should be studied to reduce the genetic and
epigenetic complexity. This will lead to systems-based approaches
of integration of data from genomic, epigenomic, transcrip-
tomic, proteomic and other platforms in more accurate statistical
models (classifiers) of diagnosis, prognosis and risk estimation.
This will also lead to a better understanding of gene–gene (29)
and gene–environment interactions (69) in ASD. Clearly, autism
researchers, and ultimately individuals with ASD, may have a lot
to gain from the study of epigenetics, including the generation of
robustly replicated epigenetic biomarkers for risk, diagnosis and
prognosis of ASD, which may also be used to monitor response to
future interventions (71).
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